Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 521 to 530 of 996 total matches.
Drugs for MRSA with Reduced Susceptibility to Vancomycin
The Medical Letter on Drugs and Therapeutics • May 04, 2009 (Issue 1311)
., University Hospital, Copenhagen
Dan M. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R ...
The recent Medical Letter article on vancomycin dosing and monitoring briefly mentioned use of an alternative antibiotic for treatment of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Some readers have asked for more information on this subject.
Click here to view the free full article.
Click here to view the free full article.
Colon Cleansing
The Medical Letter on Drugs and Therapeutics • May 18, 2009 (Issue 1312)
Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine
F. Estelle R. Simons, M.D., University ...
Web sites and blogs are advising patients that periodic "cleansing" of the colon is necessary to rid the body of toxins.
In Brief: Prevention of Stroke in Patients with Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jun 01, 2009 (Issue 1313)
. Mukherjee, M.D., F.A.C.C., Yale School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba ...
Atrial fibrillation increases the risk of stroke by a factor of 5. A randomized controlled trial (ACTIVE W) in 6706 patients with atrial fibrillation and one or more additional risk factors (≥75 years old; hypertension; previous stroke, transient ischemic attack or non- CNS embolus; left ventricular ejection fraction <45%; peripheral vascular disease; or 55-74 years old plus diabetes or coronary artery disease) found that a vitamin K antagonist such as warfarin (Coumadin, and others) was superior to clopidogrel (Plavix) plus aspirin in preventing vascular events, especially ischemic...
In Brief: Biennial IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jun 29, 2009 (Issue 1315)
., University Hospital, Copenhagen
Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine
F. Estelle R ...
The FDA, which had previously approved intravenous (IV) administration of 5 mg of zoledronic acid (Reclast – Novartis) once a year for treatment of postmenopausal osteoporosis (Med Lett Drugs Ther 2007; 49:89), has now approved the same dose for use once every 2 years to prevent osteoporosis in postmenopausal women with osteopenia.Clinical Studies – In an unpublished study summarized in the package insert, 224 women with osteopenia ≤5 years after menopause were given an IV infusion of zoledronic acid 5 mg or placebo; 2 years later, total hip bone mineral density (BMD) had increased by...
In Brief: Heat and Transdermal Fentanyl
The Medical Letter on Drugs and Therapeutics • Aug 10, 2009 (Issue 1318)
., University Hospital, Copenhagen
Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine
F. Estelle R ...
Transdermal fentanyl (Duragesic, and others) offers a convenient delivery system for patients with chronic pain1 but it has some drawbacks. One is that exposing the patch to heat, either from an external source, increased exertion or possibly high fever, could increase release of the drug, which might lead to an overdose and fatal respiratory depression.2 A recent article in the NY Times about this problem may have aroused the concerns of some patients using the patches.3First approved for marketing by the FDA in 19914, transdermal fentanyl provides continuous delivery of the drug for about 3...
Bromocriptine (Cycloset) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Dec 13, 2010 (Issue 1353)
for treatment of diabetes. o
1. R Scranton and A Cincotta. Bromocriptine – unique formulation
of a dopamine ...
The FDA has approved a new tablet formulation of
bromocriptine mesylate (Cycloset – VeroScience) for
treatment of type 2 diabetes in adults. Bromocriptine
(Parlodel, and others) is an ergot-derived dopamine
agonist that has been used for more than 20 years to
treat hyperprolactinemia, acromegaly, Parkinson’s disease
and restless leg syndrome.
Continuous Glucose Monitoring
The Medical Letter on Drugs and Therapeutics • May 02, 2011 (Issue 1363)
monitoring
and intensive treatment of type 1 diabetes. N Engl J Med 2008;
359:1464.
5. R Tanenberg et al ...
A variety of continuous glucose monitoring (CGM)
devices have been used in an effort to reduce the hypoglycemia
and wide glucose excursions that complicate
insulin treatment of diabetes. Since the last Medical
Letter issue reviewing such devices, some new devices
and some new data on old devices have become available.
The devices currently marketed in the US for personal
use are listed in Table 1.
Linagliptin (Tradjenta) - A New DPP-4 Inhibitor for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jun 27, 2011 (Issue 1367)
, placebo-controlled study. Diabetes
Obes Metab 2011;13:65.
7. R Gomis et al. Efficacy and safety ...
Linagliptin (Tradjenta – Boehringer Ingelheim/Lilly), a
third oral dipeptidyl peptidase-4 (DPP-4) enzyme
inhibitor, was recently approved by the FDA for treatment
of type 2 diabetes, either alone or in combination
with metformin, a sulfonylurea or pioglitazone
Canakinumab (Ilaris) for Systemic Juvenile Idiopathic Arthritis
The Medical Letter on Drugs and Therapeutics • Aug 19, 2013 (Issue 1423)
1. Tocilizumab (Actemra) for rheumatoid arthritis. Med Lett Drugs
Ther 2010; 52:47.
2. R Gurion et ...
The FDA has approved the interleukin-1 (IL-1) beta
inhibitor canakinumab (Ilaris – Novartis) for treatment of
systemic juvenile idiopathic arthritis (sJIA; formerly
called juvenile rheumatoid arthritis or Still’s disease) in
children ≥2 years old. Canakinumab was approved earlier
for treatment of cryopyrin-associated periodic syndromes
(CAPS). Tocilizumab (Actemra), an interleukin-6
(IL-6) inhibitor that has been available since 2010 for
treatment of rheumatoid arthritis in adults, was also
recently approved by the FDA for sJIA. Canakinumab is
the only IL-1 inhibitor approved...
Vortioxetine (Trintellix) for Depression
The Medical Letter on Drugs and Therapeutics • Nov 25, 2013 (Issue 1430)
. R Jain et al. A randomized, double-blind, placebo-controlled 6-
wk trial of the efficacy ...
The FDA has approved vortioxetine (vor" tye ox' e teen;
Trintellix – Takeda/Lundbeck), a new serotonergic drug,
for treatment of major depressive disorder. Like vilazodone
(Viibryd), another serotonergic antidepressant,
it has been claimed to have a low incidence of sexual
side effects and no significant effect on weight.